



Food and Drug Administration  
CBER/OCBQ/DBSQC

**From:** Hsiaoling Wang, Ph.D. LACBRP, DBSQC  
Alfred Del Grosso, Ph.D. LACBRP, DBSQC

**Subject:** Testing Memo for (b) (4)  
(b) (4) of Antihemophilic Factor (Recombinant), Single Chain  
(rVIII-SingleChain), STN: 125591/0, from CSL Behring

**Through:** Lokesh Bhattacharyya, Ph.D. Lab Chief LACBRP, DBSQC  
William McCormick, Ph.D. Director DBSQC

### Summary

Six lots of single chain recombinant factor VIII (rVIII-SingleChain) drug product (DP), STN 125591, were tested for the (b) (4) in the product by (b) (4) following the manufacturer's SOP ID Q-16-410. The proposed release specification for (b) (4) in DP is (b) (4).

Test results of four lots DP at 500 IU, 1000 IU, and 3000 IU formulations by DBSQC met the proposed specification for DP (Section 3.2.P.5.1 of the BLA submission) and showed expected (b) (4). However, results of two lots 250 IU each showed an (b) (4). The sponsor has not provided conclusive data on the identification of this (b) (4). From the (b) (4), it appears to be due to a (b) (4). The sponsor has defined (b) (4) and the proposed specification is based on this definition of (b) (4). Considering this (b) (4), the two 250 IU lots failed to meet the specification. Furthermore, the sponsor hypothesized in amendment 21 that this (b) (4) was not seen in 500 IU, 1000 IU, 2000 IU and 3000 IU DP samples because it was (b) (4) for these formulations, which would raise question about the method validation. DBSQC recommends that the sponsor should conduct an in-depth investigation to (b) (4) in the drug product. DBSQC also recommends that the sponsor develops and validates (b) (4) method for the determination of (b) (4) in the DP, which can (b) (4) present in the DP in all formulations.

### Method

(b) (4)

